{
  "id": "bb3b431c817c6fe8",
  "title": "STAT+: BridgeBio drug for genetic cause of dwarfism succeeds in key study",
  "description": "BridgeBio Pharma\u2019s experimental drug for the most common cause of dwarfism accelerated children\u2019s growth in a pivotal clinical trial.",
  "content": "BridgeBio Pharma\u2019s experimental drug for the most common cause of dwarfism accelerated children\u2019s growth in a pivotal clinical trial.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/02/12/bridgebio-dwarfism-achondroplasia-infigratinib/?utm_campaign=rss",
  "published_at": "2026-02-12T12:30:00+00:00",
  "fetched_at": "2026-02-13T00:31:20.432552+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: BridgeBio drug for genetic cause of dwarfism succeeds in key study",
    "description": "BridgeBio Pharma\u2019s experimental drug for the most common cause of dwarfism accelerated children\u2019s growth in a pivotal clinical trial.",
    "url": "https://www.statnews.com/2026/02/12/bridgebio-dwarfism-achondroplasia-infigratinib/?utm_campaign=rss",
    "published": "2026-02-12T12:30:00+00:00",
    "source": "STAT"
  }
}